Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics Limited has announced a change in the director’s interest, specifically regarding Miles Prince, who has acquired 4,273,142 ordinary shares indirectly through an on-market trade. This acquisition could potentially impact the company’s market perception and investor confidence, as it reflects a significant investment by a key director, signaling confidence in the company’s future prospects.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is listed on the Australian Securities Exchange (ASX) under the ticker CHM.
Technical Sentiment Signal: Sell
Current Market Cap: A$11.39M
See more insights into CHM stock on TipRanks’ Stock Analysis page.